Filtered By:
Specialty: Pathology
Management: European Medicines Agency (EMA)

This page shows you your search results in order of date.

Order by Relevance | Date

Total 1 results found since Jan 2013.

Skeletal Muscle Injury Biomarkers: Assay Qualification Efforts and Translation to the Clinic.
Abstract Skeletal muscle (SKM) injury or myopathy results in structural or functional defects in SKMs that can be caused by variety of factors such as (1) genetic, (2) drug-induced, (3) disease progression (cachexia), or (4) aging (sarcopenia). Creatine kinase (CK) and aspartate transaminase (AST) activity assays have been routinely used as SKM injury biomarkers, but they lack sensitivity and tissue specificity. In collaboration with the Predictive Safety Testing Consortium, we evaluated the diagnostic performance of a muscle injury biomarker panel (MIP) compared to CK and AST and their correlation with the histol...
Source: Toxicologic Pathology - October 1, 2017 Category: Pathology Authors: Goldstein RA Tags: Toxicol Pathol Source Type: research